In Silico Screening and Testing of FDA-Approved Small Molecules to Block SARS-CoV-2 Entry to the Host Cell by Inhibiting Spike Protein Cleavage
Viruses
; 14(6):1129, 2022.
Article
in English
| MDPI | ID: covidwho-1857582
ABSTRACT
The COVID-19 pandemic began in 2019, but it is still active. The development of an effective vaccine reduced the number of deaths;however, a treatment is still needed. Here, we aimed to inhibit viral entry to the host cell by inhibiting spike (S) protein cleavage by several proteases. We developed a computational pipeline to repurpose FDA-approved drugs to inhibit protease activity and thus prevent S protein cleavage. We tested some of our drug candidates and demonstrated a decrease in protease activity. We believe our pipeline will be beneficial in identifying a drug regimen for COVID-19 patients.
Search on Google
Collection:
Databases of international organizations
Database:
MDPI
Language:
English
Journal:
Viruses
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS